New antileishmanial and antitrypanosomal drugs

At a glance

Project leader : Prof. Dr. Rainer Riedl
Project team : Dr. Stefano Agnello, Dr. Michael Brand, Flavio Gall, Dr. Silvia Gazzola, Luka Raguz
Project budget : CHF 2'043'672
Project status : completed
Funding partner : CTI (KTI-Projekt / Projekt Nr. 19208.1 PFLS-LS)
Project partner : BACOBA AG
Contact person : Rainer Riedl

Description

The aim is to develop a natural product derived LEAD compound with unrivalled potency against a parasitic disease into a clinical drug candidate, through preclinical development. This includes the establishment of a detailed structure-activity relationship (SAR), medicinal chemistry and organic synthesis, ADME-Tox optimization, formulation, and in vivo studies.

Publications

Brand, Michael; Wang, Lei; Agnello, Stefano; Gazzola, Silvia; Gall, Flavio; Raguž, Luka; Kaiser, Marcel; Schmidt, Remo S.; Ritschl, Amélie; Jelk, Jennifer; Hemphill, Andrew; Mäser, Pascal; Bütikofer, Peter; Adams, Michael; Riedl, Rainer,

2021.

Antiprotozoal structure–activity relationships of synthetic leucinostatin derivatives and elucidation of their mode of action.

Angewandte Chemie: International Edition.

60(28), pp. 15613-15621.

Available from: https://doi.org/10.1002/anie.202102153
Brand, Michael; Wang, Lei; Agnello, Stefano; Gazzola, Silvia; Gall, Flavio; Raguž, Luka; Kaiser, Marcel; Schmidt, Remo S.; Ritschl, Amélie; Jelk, Jennifer; Hemphill, Andrew; Mäser, Pascal; Bütikofer, Peter; Adams, Michael; Riedl, Rainer,

2021.

Antiprotozoische Struktur‐Aktivitäts‐Beziehungen von synthetischen Leucinostatin‐Derivaten und Aufklärung ihres Wirkprinzips.

Angewandte Chemie.

133(28), pp. 15741-15749.

Available from: https://doi.org/10.1002/ange.202102153

go back